1. Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
- Author
-
M. Pariali, Patrizia Brigidi, Luigi Ricciardiello, Anna Prossomariti, Manuela Minguzzi, Clarissa Consolandi, Elena Biagi, Eleonora Scaioli, Chiara Fazio, Franco Bazzoli, Pasquale Chieco, Matteo Bellanova, Alessandra Munarini, Andrea Belluzzi, Giulia Piazzi, Tiziana Balbi, Marco Candela, Prossomariti, Anna, Scaioli, Eleonora, Piazzi, Giulia, Fazio, Chiara, Bellanova, Matteo, Biagi, Elena, Candela, Marco, Brigidi, Patrizia, Consolandi, Clarissa, Balbi, Tiziana, Chieco, Pasquale, Munarini, Alessandra, Pariali, Milena, Minguzzi, Manuela, Bazzoli, Franco, Belluzzi, Andrea, and Ricciardiello, Luigi
- Subjects
Male ,0301 basic medicine ,Colorectal cancer ,Pilot Projects ,Fatty Acids, Nonesterified ,Gastroenterology ,Cancer prevention ,Medicine ,Phosphorylation ,Aged, 80 and over ,chemistry.chemical_classification ,Omega-3 ,Multidisciplinary ,Microbiota ,Middle Aged ,Eicosapentaenoic acid ,Ulcerative colitis ,Interleukin-10 ,Treatment Outcome ,Eicosapentaenoic Acid ,KLF4 ,Differentiation ,Female ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,Adult ,STAT3 Transcription Factor ,medicine.medical_specialty ,Science ,Kruppel-Like Transcription Factors ,Inflammation ,Article ,Kruppel-Like Factor 4 ,Young Adult ,03 medical and health sciences ,Internal medicine ,Humans ,Colitis ,Aged ,Ulcerative coliti ,business.industry ,Fatty acid ,medicine.disease ,030104 developmental biology ,Gene Expression Regulation ,chemistry ,Suppressor of Cytokine Signaling 3 Protein ,Transcription Factor HES-1 ,Colitis, Ulcerative ,Calprotectin ,business ,Leukocyte L1 Antigen Complex - Abstract
Patients with long-standing ulcerative colitis (UC) have an increased colorectal cancer (CRC) risk. In this pilot study we evaluated the effect of Eicosapentaenoic acid as free fatty acid (EPA-FFA) supplementation on mucosal disease activity, colonic differentiation markers and microbiota composition in UC patients. Twenty long-standing UC patients in stable clinical remission and with fecal calprotectin (FC) > 150 µg/g were enrolled (T0) and supplemented with EPA-FFA 2 g/daily for 90 days (T3). Endoscopic and histologic disease activities were measured by Mayo and Geboes scores, respectively. HES1, KLF4, STAT3, IL-10 and SOCS3 levels were determined using western blotting and qRT-PCR, while phospho-STAT3 levels were assessed by western blotting. Goblet cells were stained by Alcian blue. Microbiota analyses were performed on both fecal and colonic samples. Nineteen patients completed the study; seventeen (89.5%) were compliant. EPA-FFA treatment reduced FC levels at T3. Patients with FC > 150 µg/g at T3 (n = 2) were assumed as non-responders. EPA-FFA improved endoscopic and histological inflammation and induced IL-10, SOCS3, HES1 and KLF4 in compliant and responder patients. Importantly, long-term UC-driven microbiota composition was partially redressed by EPA-FFA. In conclusion, EPA-FFA supplementation reduced mucosal inflammation, promoted goblet cells differentiation and modulated intestinal microbiota composition in long-standing UC patients.
- Published
- 2017